RLAY Latest News

Relay Therapeutics to Present Initial Clinical Data on Zovegalisib in Vascular Anomalies at the International Society for the Study of Vascular Anomalies World Congress 2026

globenewswire.com — Apr 2, 2026

CAMBRIDGE, Mass. , April 02, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc.

Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet.

fool.com — Mar 19, 2026

Nextech Invest increased its stake in Relay Therapeutics by 855,097 shares; the estimated trade value was ~$6. 1 million based on average quarterly pr

Relay Therapeutics' Cancer Drug Hits 11.1-Month Progression Free Survival - What Does This Means For Pretreated Breast Cancer Patients?

benzinga.com — Mar 16, 2026

The data revealed on Monday that the 400mg BID fed regimen of zovegalisib demonstrated a median progression-free survival (PFS) of 11. 1 months in hea

Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026

globenewswire.com — Mar 16, 2026

400mg BID fed is the dose used in the ongoing Phase 3 ReDiscover-2 trial, which initiated mid-2025 11. 1-month median PFS in heavily pre-treated patie

Relay Therapeutics (NASDAQ:RLAY) Hits New 52-Week High on Analyst Upgrade

defenseworld.net — Mar 14, 2026

Relay Therapeutics, Inc. (NASDAQ: RLAY - Get Free Report) shares hit a new 52-week high during mid-day trading on Friday after Guggenheim raised thei